In accordance with the putative role of A2AR as a therapeutic target in AD, it was reported that A2AR levels are increased in the hippocampus of AD patients, in astroglial cells (Angulo et al., 2003; Orr et al., 2015), and also in the frontal cortex of AD (Albasanz et al., 2008). The gene discussed is ADORA2A; the disease is Alzheimer disease.